BioSpace News Archive

Fuse Oncology (Fuse), a leading innovator in cutting-edge radiation oncology solutions, announced today a strategic collaboration with the University of Michigan, a recognized leader in radiation oncology.

The U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law.

ROME Therapeutics announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase.

enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that it has posted Company highlights and materials from the recently held 50th Annual VEITH Symposium on the enVVeno website.

XVIVO Perfusion AB As communicated on July 12, 2023, XVIVO has decided to close its´ PrimECC study for further patient inclusions and to evaluate potential strategic opportunities.

On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University’s esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians, Said Ibrahim, MD, MBA, MPH.

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date.

Ionis Pharmaceuticals, Inc. announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.